–The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 74th pre…


Previous articlePT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood
Next articlePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products